Indivior PLC (NASDAQ:INDV) Stock Has Average Target Price of $45.17 According to Analysts

Shares of Indivior PLC (NASDAQ:INDV) have been given a consensus recommendation of “Buy” by the seven research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $45.17.

Several brokerages recently weighed in on INDV. Barclays decreased their target price on Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, August 5th. Weiss Ratings downgraded shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Craig Hallum restated a “buy” rating and set a $53.00 price objective on shares of Indivior in a research report on Tuesday, August 4th. Finally, Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 2nd.

Insiders Place Their Bets

In other Indivior news, CAO Woodrow D. Anderson bought 1,500 shares of Indivior stock in a transaction that occurred on Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the acquisition, the chief accounting officer owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. This represents a 5.74% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.74% of the company’s stock.

Institutional Investors Weigh In On Indivior

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd grew its holdings in shares of Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after acquiring an additional 460 shares during the last quarter. Rockefeller Capital Management L.P. raised its holdings in Indivior by 512.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after buying an additional 1,076 shares during the period. TD Waterhouse Canada Inc. purchased a new position in shares of Indivior in the second quarter worth approximately $63,000. GAMMA Investing LLC acquired a new stake in shares of Indivior during the second quarter valued at approximately $66,000. Finally, Farther Finance Advisors LLC lifted its position in shares of Indivior by 716.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,624 shares of the company’s stock valued at $130,000 after acquiring an additional 3,180 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Stock Down 3.6%

INDV stock opened at $34.16 on Thursday. The company has a 50-day simple moving average of $36.13 and a 200 day simple moving average of $36.72. The company has a market capitalization of $4.03 billion, a P/E ratio of 12.24 and a beta of 0.87. Indivior has a fifty-two week low of $23.72 and a fifty-two week high of $42.81.

Indivior (NASDAQ:INDV) last released its earnings results on Tuesday, June 30th. The company reported $5.75 EPS for the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. The firm had revenue of $343.00 million for the quarter. Equities analysts anticipate that Indivior will post 3.66 EPS for the current year.

Indivior Announces Dividend

The firm also recently announced a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be paid a dividend of $8.13 per share. The ex-dividend date of this dividend is Friday, October 30th.

About Indivior

Indivior PLC (NASDAQ: INDV) is a specialty pharmaceutical company focused on developing and commercializing treatments for substance use disorders and serious mental health conditions. The company’s primary focus is opioid use disorder, with products designed to support patients through medication-assisted treatment and recovery.

Indivior’s portfolio includes Sublocade, an extended-release injectable formulation of buprenorphine; Suboxone, a buprenorphine and naloxone product available in sublingual formulations; and Perseris, an extended-release injectable formulation of risperidone for schizophrenia.